Matching articles for "mNEXSPIKE"

COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19

   
The Medical Letter on Drugs and Therapeutics • July 21, 2025;  (Issue 1733)
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe...
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe outcomes from COVID-19. Spikevax, the original Moderna mRNA COVID-19 vaccine, remains in production2; it is licensed for use in persons ≥12 years old and is available under an Emergency Use Authorization (EUA) for children 6 months to 11 years old.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):119-20 | Show Full IntroductionHide Full Introduction